Regulatory Compliance Disclosure

NATCO Pharma Limited has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) regarding the inspection conducted at its Finished Dosage Formulations (FDF) manufacturing plant located in Parawada, Visakhapatnam, Andhra Pradesh, India.

Inspection Details

The US FDA inspection was conducted from August 17th to August 21st, 2026. At the conclusion of the inspection, the Company received 4 (Four) observations in Form-483.

Inspection Outcome Classification

The US FDA has classified the inspection as Voluntary Action Indicated (VAI). This classification indicates that objectionable conditions were found during the inspection but do not require regulatory or administrative action by the FDA.

Plant Significance

The Visakhapatnam FDF Unit is a manufacturing facility that produces finished dosage formulations for distribution to global markets, including the United States. The facility holds approvals from multiple regulatory authorities including US FDA, Brazil ANVISA, Health Canada, and WHO, serving 50+ global markets.

Reference to Previous Communication

This disclosure references the company's earlier intimation dated August 21st, 2026, regarding the same inspection matter.